A medicinal chemists’ guide to the unique difficulties of lead optimization for tuberculosis.
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Journal:Bioorganic & medicinal chemistry letters, Volume: 23, Issue: 17
Tuberculosis is a bacterial disease that predominantly affects the lungs and results in extensive tissue pathology. This pathology contributes to the complexity of drug development as it presents discrete microenvironments within which the bacterium resides, often under conditions where replication is limited and intrinsic drug susceptibility is low. This consolidated pathology also results in impaired vascularization that limits access of potential lead molecules to the site of infection. Translating these considerations into a target-product profile to guide lead optimization programs involves implementing unique in vitro and in vivo assays to maximize the likelihood of developing clinically meaningful candidates.